Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sab Biotherapeutics Inc 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 USA

www.sabbiotherapeutics.com P: 605-679-6980

Description:

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.

Key Statistics

Overview:

Market Capitalization, $K 37,179
Enterprise Value, $K -19,391
Shares Outstanding, K 9,226
Annual Sales, $ 2,240 K
Annual Net Income, $ -42,190 K
Last Quarter Sales, $ 310 K
Last Quarter Net Income, $ -22,860 K
EBIT, $ -38,070 K
EBITDA, $ -34,320 K
60-Month Beta 0.78
% of Insider Shareholders 25.95%
% of Institutional Shareholders 7.82%
Float, K 6,831
% Float 74.05%
Short Volume Ratio 0.03

Growth:

1-Year Return -53.68%
3-Year Return -95.93%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.00 on 11/13/23
Latest Earnings Date 05/21/24
Earnings Per Share ttm -3.90
EPS Growth vs. Prev Qtr 28.57%
EPS Growth vs. Prev Year 37.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 01/05/24

SABS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -144.66%
Return-on-Assets % -88.65%
Profit Margin % -1,883.48%
Debt/Equity 0.00
Price/Sales 16.56
Price/Cash Flow N/A
Price/Book 0.66
Book Value/Share 6.21
Interest Coverage -130.84
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar